Advertisement

Topics

Sofinnova Ventures Company Profile

03:34 EDT 20th June 2018 | BioPortfolio

Sofinnova Ventures we are company builders who work with our entrepreneurs as a team. Our firm, based in San Francisco and founded in 1974, invests venture capital in early-stage Life Science and Information Technology startup companies. Our mission is to provide entrepreneurs with the resources, experience and skill sets necessary to grow early-stage companies into great businesses.Sofinnova Ventures combines extensive venture-capital experience with deep technical, startup and operational management. We are experienced entrepreneurs, having founded, operated, acquired, sold, and taken public companies in our operational careers. We run Sofinnova Ventures itself in an aggressive, smart, entrepreneurial fashion.While our primary value to entrepreneurs is our experience and the active, company-building help we offer, we also offer trans-Atlantic synergy and market acceleration to our entrepreneurs. Because of our strong ties to Europe's leading financial, technology and venture companies, we help U.S. companies quickly enter Europe's booming markets, and our European companies to develop a strong presence in the strategic U.S. high-tech markets.

Location

140 Geary Street Tenth floor
San Francisco
California
94108
United States of America

Contact

Phone: 415 228 3380
Fax: 415 228 3390
Email: info@sofinnova.com


News Articles [333 Associated News Articles listed on BioPortfolio]

Neurana brings in $60mm Series A round

CNS-focused Neurana Pharmaceuticals Inc. (formerly Katama) closed a $60mm Series A round led by Sofinnova Ventures. New Leaf Venture Partners, HIG BioHealth Partners, Longitude Capital, and MagnaSci V...

Sofinnova crosses over

Sofinnova Partners raised its first crossover fund to attract international investors to late-stage EU biotechs.

$340M life sciences crossover fund launched by Sofinnova Partners

The life sciences-focused Sofinnova Crossover Fund I was launched by Paris-based venture capital firm Sofinnova Partners afte -More- 

Antoine Papiernik, Managing Partner: How Sofinnova Partners achieve high returns through taking calculated risks.

Sofinnova invest early in projects with disruptive technologies that have the potential to become strong sustainable companies with the potential to return in excess of 10x their investment. Antoine P...

French Crossover Fund Raises €275M to Invest in Medical Biotechs

Sofinnova Partners has launched a crossover fund focusing on European companies to support medical biotechs across all funding stages, from seed to late stage.  Sofinnova Partners, the largest French...

Sofinnova Targets Later Stage Firms With €275M Healthcare Crossover Fund

After four decades of exclusively backing early stage life science start-ups, French venture capitalist Sofinnova Partners has launched its first...   

RubiconMD wraps up $13.8M Series B to connect PCPs and specialists

The round, which was led by HLM Ventures and Optum Ventures, included participation from Centene Corporation, Alma Mundi Ventures and others.

Eko raises $5mm in Series A round

Eko (cardiac monitoring devices) raised $5mm in its Series A financing led by ARTIS Ventures, which was joined by Strategic Partners, Dreamlt Ventures, 1812 Ventures, and founder.org.

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Avant ex [B4 Ventures LLC]

B4 Brands: Avant EX Instant Hand Sanitizer

Avant foaming hand sanitizer [B4 Ventures LLC]

B4 Brands: Avant Foaming Hand Sanitizer - Fragrance Free

Avant original instant hand sanitizer [B4 Ventures LLC]

B4 Brands: Avant Original Instant Hand Sanitizer

Aterra antibacterial hand wash [B4 Ventures LLC]

B4 Brands: Aterra Antibacterial Hand Soap

Avant original - fragrance free [B4 Ventures LLC]

B4 Brands: Avant Original - Fragrance Free Instant Hand Sanitizer

PubMed Articles [9 Associated PubMed Articles listed on BioPortfolio]

Outsourcing of Academic Clinical Laboratories: Experiences and Lessons From the Association of Pathology Chairs Laboratory Outsourcing Survey.

American hospitals are increasingly turning to service outsourcing to reduce costs, including laboratory services. Studies of this practice have largely focused on nonacademic medical centers. In cont...

Femicide: a Avoidable Mortality? The "Tivoli" Model.

The Instabul Convention is a normative tool for the prevention of women's violence in Europe. Rome 5 Local Healthcare Authority has implemented a synergistic intervention model in joint ventures with ...

Tiny Conveyance: Micro- and Nanorobots Prepare to Advance Medicine.

In the science-fiction classic Fantastic Voyage [1], a shrink-ray zaps a submarine and the crew within it, and the resulting microscopic vehicle ventures inside a human body to destroy a blood clot an...

Evaluating Resident Perspectives on International Humanitarian Missions.

Opportunities for international missions are highly sought after by medical students, residents, and attending plastic surgeons. The educational benefits and ethical considerations of trainees partici...

With tree nut sensitization, take the current when it serves, or lose our ventures.

Tree nut allergy affects approximately 1.4-2.3%, depending on the study methodology, patient age, and region in which the study was conducted.1,2 Tree nut allergy can be severe, and tends to persist t...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Evaluation of a Digital Microscope for Malaria

Light microscopy, which is based on century-old technology, remains a key indicator in drug efficacy testing performed in the context of clinical trials for monitoring existing antimalaria...

Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2)

Microscopy remains a key indicator in drug efficacy testing performed in the context of clinical trials for monitoring existing antimalarials or in the context of regulatory clinical trial...

Companies [548 Associated Companies listed on BioPortfolio]

Sofinnova Ventures

Sofinnova Ventures we are company builders who work with our entrepreneurs as a team. Our firm, based in San Francisco and founded in 1974, invests venture capital in early-stage Life Science and Info...

Sofinnova Partners

1972 Sofinnova is the first venture capital company created in France.Sofinnova Partners is an independent venture capital company based in Paris. We have special relations with Sofinnova Ventures, o...

NuCana

NuCana® is a rapidly growing, clinical stage biopharmaceutical company with a broad development portfolio of novel anti-cancer medicines. The Company’s proprietary ProTide...

Marinus Pharmaceuticals, Inc.

Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. Marinus ...

Catalyst Biosciences, Inc.

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery p...

More Information about "Sofinnova Ventures" on BioPortfolio

We have published hundreds of Sofinnova Ventures news stories on BioPortfolio along with dozens of Sofinnova Ventures Clinical Trials and PubMed Articles about Sofinnova Ventures for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sofinnova Ventures Companies in our database. You can also find out about relevant Sofinnova Ventures Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record